In8 Bio, Inc. financial data

Symbol
INAB on Nasdaq
Location
Empire State Building, 350 5 Th Avenue, Suite 5330, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q1 2025 - May 7, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 310 %
Debt-to-equity 56.8 %
Return On Equity -217 % -43.3%
Return On Assets -138 %

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 90.8M shares +110%
Common Stock, Shares, Outstanding 81.3M shares
Entity Public Float 29M USD +27.8%
Common Stock, Value, Issued 8K USD
Weighted Average Number of Shares Outstanding, Basic 83.5M shares +92.9%
Weighted Average Number of Shares Outstanding, Diluted 83.5M shares +92.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 15M USD -13.3%
General and Administrative Expense 11.6M USD -16%
Operating Income (Loss) -27.4M USD +11.7%
Net Income (Loss) Attributable to Parent -27.4M USD +11.7%
Earnings Per Share, Basic 0 USD/shares +51.1%
Earnings Per Share, Diluted 0 USD/shares +51.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current 427K USD -20.8%
Assets, Current 12.7M USD
Property, Plant and Equipment, Net 2.6M USD -21.7%
Operating Lease, Right-of-Use Asset 3.17M USD
Other Assets, Noncurrent 275K USD
Assets 19.9M USD
Accounts Payable, Current 575K USD
Accrued Liabilities, Current 1.15M USD +27.9%
Liabilities, Current 2.96M USD
Operating Lease, Liability, Noncurrent 2.85M USD -25.7%
Liabilities 5.99M USD
Retained Earnings (Accumulated Deficit) -127M USD
Stockholders' Equity Attributable to Parent 13.9M USD -20.8%
Liabilities and Equity 19.9M USD

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -3.12M USD +60.6%
Net Cash Provided by (Used in) Financing Activities 3.89M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 490M shares 0%
Common Stock, Shares, Issued 81.3M shares
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 771K USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12.2M USD -8.39%
Deferred Tax Assets, Valuation Allowance 25.2M USD +28.3%
Deferred Tax Assets, Gross 26.2M USD +27%
Operating Lease, Liability 3.51M USD -25.1%
Depreciation 993K USD +3.65%
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Lessee, Operating Lease, Liability, to be Paid 4.38M USD -28.3%
Operating Lease, Liability, Current 661K USD -22.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.22M USD -13.6%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.42M USD +1.07%
Operating Lease, Weighted Average Discount Rate, Percent 0.13 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 870K USD -38.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 891K USD -27.2%
Deferred Tax Assets, Operating Loss Carryforwards 2.7M USD
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 120K USD -86.5%
Additional Paid in Capital 141M USD
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 19.6M USD +41.3%
Share-based Payment Arrangement, Expense 4.59M USD -3.37%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares